Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 181

1.

Effects of smartphone use with and without blue light at night in healthy adults: A randomized, double-blind, cross-over, placebo-controlled comparison.

Heo JY, Kim K, Fava M, Mischoulon D, Papakostas GI, Kim MJ, Kim DJ, Chang KJ, Oh Y, Yu BH, Jeon HJ.

J Psychiatr Res. 2016 Dec 12;87:61-70. doi: 10.1016/j.jpsychires.2016.12.010. [Epub ahead of print]

PMID:
28017916
2.

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Cardiac, Endocrine, Metabolic, and Motoric Effects in a Randomized, Double-Blind, Placebo-Controlled Study.

Mischoulon D, Shelton RC, Baer L, Bobo WV, Curren L, Fava M, Papakostas GI.

J Clin Psychiatry. 2016 Nov 8. doi: 10.4088/JCP.15m10426. [Epub ahead of print]

PMID:
27835715
3.

Current Trends in Identifying Rapidly Acting Treatments for Depression.

Ionescu DF, Papakostas GI.

Curr Behav Neurosci Rep. 2016 Jun;3(2):185-191.

PMID:
27574579
4.

Identifying Patients Who Need a Change in Depression Treatment and Implementing That Change.

Papakostas GI.

J Clin Psychiatry. 2016 Aug;77(8):e1009. doi: 10.4088/JCP.14077cc4c.

5.

Ziprasidone augmentation for anxious depression.

Ionescu DF, Shelton RC, Baer L, Meade KH, Swee MB, Fava M, Papakostas GI.

Int Clin Psychopharmacol. 2016 Nov;31(6):341-6. doi: 10.1097/YIC.0000000000000133.

PMID:
27306192
6.

Reduced frontal-subcortical white matter connectivity in association with suicidal ideation in major depressive disorder.

Myung W, Han CE, Fava M, Mischoulon D, Papakostas GI, Heo JY, Kim KW, Kim ST, Kim DJ, Kim DK, Seo SW, Seong JK, Jeon HJ.

Transl Psychiatry. 2016 Jun 7;6(6):e835. doi: 10.1038/tp.2016.110.

7.

Demographic variables, design characteristics, and effect sizes of randomized, placebo-controlled, monotherapy trials of major depressive disorder and bipolar depression.

Papakostas GI, Martinson MA, Fava M, Iovieno N.

J Clin Psychiatry. 2016 May;77(5):e619-24. doi: 10.4088/JCP.14r09767.

PMID:
27249092
8.

Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder.

Baek JH, Kim HJ, Fava M, Mischoulon D, Papakostas GI, Nierenberg A, Heo JY, Jeon HJ.

Psychiatry Investig. 2016 May;13(3):321-6. doi: 10.4306/pi.2016.13.3.321.

9.

Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.

Sarris J, Murphy J, Mischoulon D, Papakostas GI, Fava M, Berk M, Ng CH.

Am J Psychiatry. 2016 Jun 1;173(6):575-87. doi: 10.1176/appi.ajp.2016.15091228.

PMID:
27113121
10.
11.

Identifying patients with depression who require a change in treatment and implementing that change.

Papakostas GI.

J Clin Psychiatry. 2016 Feb;77 Suppl 1:16-21. doi: 10.4088/JCP.14077su1c.03.

12.

Relationship between placebo response rate and clinical trial outcome in bipolar depression.

Iovieno N, Nierenberg AA, Parkin SR, Hyung Kim DJ, Walker RS, Fava M, Papakostas GI.

J Psychiatr Res. 2016 Mar;74:38-44. doi: 10.1016/j.jpsychires.2015.12.016.

PMID:
26736040
13.

Association of obesity and inflammatory marker levels on treatment outcome: results from a double-blind, randomized study of adjunctive L-methylfolate calcium in patients with MDD who are inadequate responders to SSRIs.

Shelton RC, Pencina MJ, Barrentine LW, Ruiz JA, Fava M, Zajecka JM, Papakostas GI.

J Clin Psychiatry. 2015 Dec;76(12):1635-41. doi: 10.4088/JCP.14m09587.

PMID:
26613389
14.

The pro-inflammatory profile of depressed patients is (partly) related to obesity.

Shelton RC, Falola M, Li L, Zajecka J, Fava M, Papakostas GI.

J Psychiatr Res. 2015 Nov;70:91-7. doi: 10.1016/j.jpsychires.2015.09.001.

15.

Antidepressants and their effect on cognition in major depressive disorder.

Papakostas GI.

J Clin Psychiatry. 2015 Aug;76(8):e1046. doi: 10.4088/JCP.13086tx5c. Review.

16.

Reply to commentary by Rothschild: "A Blood Test for Depression?".

Papakostas GI, Shelton RC, Henry ME, Bilello JA.

J Clin Psychiatry. 2015 Aug;76(8):e1038. doi: 10.4088/JCP.15lr10018. No abstract available.

PMID:
26335092
17.

Towards new mechanisms: an update on therapeutics for treatment-resistant major depressive disorder.

Papakostas GI, Ionescu DF.

Mol Psychiatry. 2015 Oct;20(10):1142-50. doi: 10.1038/mp.2015.92. Review.

PMID:
26148812
18.

Influence of anxiety symptoms on improvement of neurocognitive functions in patients with major depressive disorder: A 12-week, multicenter, randomized trial of tianeptine versus escitalopram, the CAMPION study.

Yoo I, Woo JM, Lee SH, Fava M, Mischoulon D, Papakostas GI, Kim EJ, Chung S, Ha JH, Jeon HJ.

J Affect Disord. 2015 Oct 1;185:24-30. doi: 10.1016/j.jad.2015.06.038.

PMID:
26142691
19.

Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.

Papakostas GI, Fava M, Baer L, Swee MB, Jaeger A, Bobo WV, Shelton RC.

Am J Psychiatry. 2015 Dec;172(12):1251-8. doi: 10.1176/appi.ajp.2015.14101251.

20.

Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial.

Sarris J, Price LH, Carpenter LL, Tyrka AR, Ng CH, Papakostas GI, Jaeger A, Fava M, Mischoulon D.

Pharmacopsychiatry. 2015 Jul;48(4-5):141-4. doi: 10.1055/s-0035-1549928.

PMID:
26011569
Items per page

Supplemental Content

Loading ...
Support Center